Biology of idh mutant cholangiocarcinoma
WebDuring my postdoctoral studies, I have concentrated on the biology of IDH mutant cholangiocarcinoma. I have generated a series of novel genetically engineered mouse models of cholangiocarcinoma harboring mutations in IDH1 in combination with different oncogene/tumor suppressor mutations found in the human disease. I have used these … WebRecognition of the high frequency of IDH mutations in glioma [and also in other malignancies, including acute myeloid leukemia (AML) and cholangiocarcinoma] have led to the development of a number of targeted agents that can inhibit these enzymes. Enasidenib and ivosidenib have both gained regulatory approval for IDH mutant AML.
Biology of idh mutant cholangiocarcinoma
Did you know?
WebSep 20, 2024 · Due to the critical role of IDH mutation in several types human malignancies, pharmacological grade inhibitors have been developed to suppress the neomorphic activity of IDH mutant enzymes (25, 26). Several IDH mutant inhibitors are currently examined through clinical studies, such as AG-120 (e.g., NCT02073994 and NCT02074839), AG … Webthat regulate epigenetics, DNA repair, metabolism, and other processes. Among epithelial malignancies, IDH mutations are particularly common in intrahepatic …
WebJan 20, 2024 · Prior ClarIDHy data showed that ivosidenib led to a 63% reduction in the risk of disease progression or death versus placebo in previously treated patients with IDH1-mutant advanced … WebCholangiocarcinomas are rare, aggressive tumors, with an increasing incidence (mainly of the intrahepatic subgroup) and poor prognosis. 1,2 The median survival among patients with advanced disease is approximately …
WebAmong these, isocitrate dehydrogenase (IDH) mutations have been reported in approximately 15-20% of intrahepatic cholangiocarcinoma (iCCA) patients, while these aberrations are considered to be less frequent in perihilar CCA (pCCA), distal CCA (dCCA), and gallbladder cancer. Of note, the recent findings of the ClarIDHy phase III trial add to ... WebThe targeted drugs developed according to IDH mutations have entered clinical trials, and some drugs have been involved in clinical treatment ( 10 – 12 ). In this review, we discuss the biological roles and therapeutic applications of IDH2 mutations in human cancers. FIGURE 1. Figure 1 The roles of IDHs in cancer metabolism.
WebSep 30, 2024 · The ClarIDHy trial is a global, randomized Phase 3 trial in previously treated IDH1 mutant cholangiocarcinoma patients who have documented disease progression following one or two systemic ...
WebJul 27, 2024 · Glioblastoma is the most common and aggressive primary brain tumor. Despite standard multimodality therapy, median overall survival remains poor with a 5-year survival rate of approximately 5% in most studies (range 4.7–13.0%). Strong interest in targeting IDH mutations has led to a variety of studies in both hematologic malignancies … the paper silicon led 台灯WebInhibition of mutant IDH1 is being evaluated clinically as a treatment option for oncology. Here we describe the structure-based design and optimization of quinoline lead compounds to identify FT-2102, a potent, orally bioavailable, brain penetrant, and selective mIDH1 inhibitor. FT-2102 has excellent ADME/PK properties and reduces 2-hydroxyglutarate … shuttlecsp11_3003WebWe read with interest the Article by Ghassan Abou-Alfa and colleagues1 about ivosidenib in IDH1-mutant chemotherapy-refractory cholangiocarcinoma. Ivosidenib significantly … the paper snowflake companyWebApr 9, 2024 · Introduction: Cholangiocarcinomas (CCAs) are rare and heterogeneous malignancies associated with poor prognosis, with most of the patients presenting … the paper snowflake company ltdWebJun 3, 2024 · Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2.These recurrent ... shuttle crossings to franceWebFeb 28, 2024 · Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes across human cancers.These hotspot gain-of-function mutations cause the IDH enzyme to aberrantly … the papers of dwight david eisenhowerWebFeb 28, 2024 · Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are the most frequently mutated metabolic genes across human cancers. These hot-spot gain-of-function … the papers milford indiana